Evidence map›Paper›PMID 34834585›Full record

ArticleJournal of personalized medicine2021

Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study.

Zulfan Zazuli, Corine de Jong, Wei Xu, Susanne J H Vijverberg, Rosalinde Masereeuw, Devalben Patel, Maryam Mirshams, Khaleeq Khan, Dangxiao Cheng, Bayardo Ordonez-Perez and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 12 institutions in 3 countries.

Zulfan ZazuliDepartment of Respiratory Medicine, Academic Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-1264-9558
Corine de JongDepartment of Clinical Pharmacy, St. Antonius Hospital, 3430 EM Nieuwegein, The Netherlands.ORCID 0000-0003-0746-5057
Wei XuDepartment of Biostatistics, Dalla Lana School of Public Health, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Susanne J H VijverbergDepartment of Respiratory Medicine, Academic Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Rosalinde MasereeuwDivision of Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.ORCID 0000-0002-1560-1074
Devalben PatelDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Maryam MirshamsDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Khaleeq KhanDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Dangxiao ChengDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Bayardo Ordonez-PerezDepartment of Laboratory Medicine and Pathology, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada.
Shaohui HuangDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Anna SpreaficoDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Aaron R HansenDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
David P GoldsteinDepartment of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
John R de AlmeidaDepartment of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Scott V BratmanDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Andrew HopeDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Jennifer J KnoxDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Rebecca K S WongDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
Gail E DarlingDepartment of Thoracic Surgery, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada.
Abhijat KitchluDepartment of Medicine, Nephrology, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Simone W A van HaarlemDepartment of Pulmonology, St Antonius Hospital, 3430 EM Nieuwegein, The Netherlands.
Femke van der MeerDepartment of Pulmonology, Diakonessenhuis, 3582 KE Utrecht, The Netherlands.
Anne S R van LindertDepartment of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Alexandra Ten HeuvelDepartment of Pulmonology, Groene Hart Hospital, 2803 HH Gouda, The Netherlands.
Jan BrouwerDepartment of Pulmonology, Rivierenland Hospital, 4002 WP Tiel, The Netherlands.
Colin J D RossBritish Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.ORCID 0000-0003-1476-7037
Bruce C CarletonBritish Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.ORCID 0000-0002-4485-4054
Toine C G EgbertsDepartment of Clinical Pharmacy, Division Laboratories, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.ORCID 0000-0003-1758-7779
Gerarda J M HerderMeander Medical Center, Department of Pulmonology, 3813 TZ Amersfoort, The Netherlands.
Vera H M DeneerDepartment of Clinical Pharmacy, Division Laboratories, Pharmacy, and Biomedical Genetics, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Anke H Maitland-van der ZeeDepartment of Respiratory Medicine, Academic Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-0414-3442
Geoffrey LiuDivision of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.
University of Toronto · CAUniversity Health Network · CAUtrecht University · NLAmsterdam UMC Location University of Amsterdam · NLUniversity Medical Center Utrecht · NLUniversity of British Columbia · CABandung Institute of Technology · IDDiakonessenhuis hospital · NLGroene Hart Ziekenhuis · NLMeander Medisch Centrum · NLSt. Antonius Ziekenhuis · NLZiekenhuis Rivierenland · NL

Funding

Indonesia Endowment Fund for Education (LPDP) 20161022049506
6 · The paper itself

Abstract

This study aims to evaluate genetic risk factors for cisplatin-induced nephrotoxicity by investigating not previously studied genetic risk variants and further examining previously reported genetic associations. A genome-wide study (GWAS) was conducted in genetically estimated Europeans in a discovery cohort of cisplatin-treated adults from Toronto, Canada, followed by a candidate gene approach in a validation cohort from the Netherlands. In addition, previously reported genetic associations were further examined in both the discovery and validation cohorts. The outcome, nephrotoxicity, was assessed in two ways: (i) decreased estimated glomerular filtration rate (eGFR), calculated using the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) and (ii) increased serum creatinine according to the Common Terminology Criteria for Adverse Events v4.03 for acute kidney injury (AKI-CTCAE). Four different Illumina arrays were used for genotyping. Standard quality control was applied for pre- and post-genotype imputation data. In the discovery cohort (

Indexed as

cisplatingenetic polymorphismsgenome-wide association studykidney injurynephrotoxicitypharmacogenomicsplatinum

Identifiers

PMID34834585
PMCPMC8623115
OpenAlexW3216493769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.